| Today’s Big NewsMar 25, 2025 |
|
Thursday, April 3, 2025 | 11am ET / 8am PT Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT (Cleaved, Linearized with Protein Template) technology. Learn more about this groundbreaking technology designed to improve the efficiency of genome editing. Register now.
|
|
| By James Waldron Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. |
|
|
|
By Nick Paul Taylor Cassava Sciences has given up on simufilam in Alzheimer’s disease. Months after seeing one phase 3 trial fail, the biotech is planning to stop development altogether after chalking up another late-stage flop. |
By Gabrielle Masson President Donald Trump’s Department of Government Efficiency has again revised savings estimates tied to federal site closures, nearly halving the unit’s initial forecast. The agency has also removed 91 federal sites previously listed on its “wall of receipts” for planned lease cancellations, including three FDA sites. |
By James Waldron Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 inhibitor as a dermatology treatment in Japan. |
By Gabrielle Masson The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. |
By Darren Incorvaia A New Jersey-based biotech is looking to become the main character in the age-related macular degeneration field. Character Biosciences has landed a $93 million series B to progress its precision medicine candidates through clinical development. |
By Darren Incorvaia After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of a natural experiment to look for more definitive evidence that the shot can reduce dementia risk. |
By Angus Liu After threatening a month ago to impose “25% or higher” tariffs on foreign-made pharmaceuticals, President Donald Trump has doubled down on the pledge, although the exact timing and scope of their implementation remains unclear. |
By Dave Muoio The public health agency's current acting director has a background in biomedical research and 20 years of experience within government bodies. |
By Nick Paul Taylor The PMCPA has dug into the industry’s LinkedIn activities once again. AstraZeneca received the harshest censure in the latest set of cases, taking a telling-off over one of its own posts, while Pfizer escaped with a slap on the wrist after its employees got too liberal with their LinkedIn likes. |
By Conor Hale Abbott's approach will use high-energy sound pressure waves to crack obstructive deposits within the blood vessel before the placement of a stent. |
Fierce podcastsDon’t miss an episode |
| | Executive Editor Heather Landi and Senior Writer Paige Minemyer sit down to chat about the evolution of the Fierce 15 project and honorees. |
|
|---|
|
|
|
Tuesday, April 8, 2025 | 1pm ET / 10am PT Learn how AI-powered digital phenotyping and real-world data (RWD) help identify overlooked patient populations, bridge gaps between clinical guidelines and real-world treatment, and refine commercial strategies. Join experts to discover how AI-driven insights can optimize market positioning and ensure therapies reach the right patients. Register now!
|
|
| WhitepaperRead about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperDiscover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
| WhitepaperDevelop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| |
|
